Key Takeaways
- A cancer hospital needs not only land, building and equipment but also substantial working capital to fund oncology services after commissioning; chemotherapy drugs alone can lock up crores of rupees in inventory before any reimbursement arrives.
- Cancer hospital working capital requirement must be derived from the hospital’s revenue model, inventory policy and receivable cycle, not from a generic “current assets minus current liabilities” formula applied to other industries.
- Chemotherapy drugs, oncology consumables and insurance/TPA/government scheme receivables typically make working capital for a cancer hospital higher and more volatile than in many non-specialty hospital projects.
- Banks in India assess oncology hospital working capital based on the operating cycle, projected turnover, drawing power and promoter contribution; underestimating this requirement can strain cash flow and weaken DSCR.
- A bankable cancer hospital DPR should integrate project cost, means of finance, revenue, working capital, financial projections and repayment capacity in one consistent financial model.
Explore Cancer Hospital DPR Guides
Explore our complete series on Cancer Hospital project planning, financial analysis and bank finance.
Introduction: Why Working Capital Matters in a Cancer Hospital
Setting up an oncology hospital in India involves capital expenditure that often runs from $10-20 million to over $100 million, covering land acquisition, radiation bunkers costing $2-5 million each, linear accelerators, PET-CT scanners, and specialised civil construction. Building an oncology hospital typically takes 3-5 years from concept to commissioning. But the financial story does not end when the doors open. Operating a cancer hospital involves complex financial considerations that begin on day one of operations, when the hospital must fund high-cost chemotherapy drugs, pay specialist oncologists, cover electricity for LINACs and HVAC, and wait weeks or months for insurance and government scheme payments.
In my experience while preparing hospital DPRs, I have seen technically completed cancer hospitals with NABH-ready infrastructure struggle within months of launch because their cancer hospital working capital requirement was not realistically estimated in the business plan. The promoters planned every piece of equipment in detail but treated working capital as a residual number. That approach can be financially dangerous.
The chain of financial dependencies in any oncology project follows a clear path: Hospital Capacity leads to Patient Volume, which generates Revenue, which creates Receivables, while Operating Expenses must be paid regardless, and all of this determines the Working Capital gap, which directly affects Cash Flow and ultimately Debt Servicing capacity. Each link in this chain amplifies problems in the next. A shortfall in collections, for instance, does not reduce salaries or AMC obligations; it simply widens the working capital gap.
This article focuses on working capital for a cancer hospital or oncology centre in India, written for promoters, doctors, oncologists and investors preparing DPRs, CMA Data and project finance proposals. The distinction between fixed capital (land, building, equipment, covered separately in the article on Cancer Hospital Project Cost in India) and working capital is fundamental: both must be planned together at the project-concept stage, not sequentially.
What Is Working Capital in a Cancer Hospital?
Working capital in an oncology hospital represents the funds required to bridge the timing gap between incurring operating expenses for cancer treatment and collecting revenue from patients, insurance companies, TPAs and government health schemes. Revenue flow in cancer hospitals depends heavily on contracts with payers, and these contracts create collection lags that must be financed. India’s healthcare industry, projected to reach $150 billion, reflects the scale of this financing challenge.
The standard accounting formula is straightforward: Working Capital = Current Assets minus Current Liabilities. For a cancer hospital DPR or bank-finance proposal, this formula is only the starting point. The actual requirement must be estimated from the hospital’s planned operating cycle, covering how many days of inventory to hold, how long collections take, and how much credit vendors extend.
Key current assets in an oncology hospital include:
- Minimum cash and bank balance sufficient for 1-2 months of routine payments
- Pharmacy stock, including general medicines and supportive care drugs
- Chemotherapy and targeted-therapy drug inventory
- Radiotherapy and imaging consumables
- Surgical, ICU and operating-theatre consumables
- Pathology and molecular diagnostic reagents and kits
- PPE and infection-control supplies
- Receivables from self-pay patients, private insurance, TPAs, Ayushman Bharat and state health schemes, and corporate or institutional tie-ups
- Other current assets such as prepaid expenses and advances
Principal current liabilities include supplier credit on oncology medicines and consumables; outstanding dues for power, oxygen, medical gases, housekeeping and security; accrued salaries and consultant retainers; and short-term statutory obligations forming part of normal operations.
In a practical cancer hospital working capital assessment, the focus is on the level of inventory, receivables and operating cash buffer required to support planned cancer treatment volumes, net of realistic supplier credit.
Why Cancer Hospitals Need Significant Working Capital
Oncology hospitals differ from general hospitals on several fronts. A comprehensive cancer center requires multiple treatment modalities: medical oncology, radiation oncology, surgical oncology, diagnostics, day-care chemotherapy and in-patient care. Oncology care has lengthy treatment cycles and specialised talent demands, requiring a multidisciplinary team for high-quality care. Global oncology spending reached $193 billion in 2022, reflecting how resource-intensive this specialty is. The National Cancer Institute’s budget was $7.2 billion in fiscal year 2024, underscoring the scale of investment this field demands worldwide.
High-cost drugs and sterile supplies tie up liquid capital in ways that general hospitals rarely experience:
- Oncology medications are exceptionally expensive with limited shelf lives; hospitals typically hold 30-60 days of stock for commonly used chemotherapy protocols
- Chemotherapy drugs often have short expiration dates requiring careful inventory management and cold-chain storage
- High-cost oncology drugs can create severe cash deficits due to delayed insurer payments, since the hospital pays vendors first but receives reimbursement weeks later
- Surgical oncology consumables, implants, radiotherapy consumables and imaging contrast media add further to the inventory burden
Payroll for specialised oncology staff constitutes a major operating expense. Medical oncologists, radiation oncologists, onco-surgeons, medical physicists, dosimetrists and trained nursing staff command fixed salaries that continue regardless of patient volume. Strict safety standards for radiation handling add ongoing operational overhead, including calibration, quality assurance and accreditation compliance. The Cancer Cure Fund has disbursed Rs. 341.14 crores for over 18,000 patients, but hospital-level operating costs must still be funded continuously.
Recurring operational costs that drive cash requirement include electricity and demand charges (especially for linear accelerators and HVAC systems), medical gases and oxygen, equipment AMC/CMC payments for radiotherapy and imaging, software licences for oncology information systems, and regular quality-compliance expenses. Commission on Cancer accreditation or equivalent Indian standards add recurring compliance costs.
The collection cycle further stretches working capital needs. Insurance claims often take 30 to 90 days to settle in cancer hospitals. Government health scheme payments under Ayushman Bharat or state programmes may take 60-120 days or more. Out-of-pocket payments introduce collection risks for cancer treatment providers, since self-pay patients may delay or default. The payer mix of a hospital determines how much cash sits locked in receivables at any point.
During the first 12-24 months after commissioning, working capital pressure peaks. Occupancy is low, chemotherapy and radiotherapy volumes are still building, but fixed costs are fully incurred. Cancer hospitals face unique financial risks such as underutilization and high drug inventory costs during this period.
Major Components of Cancer Hospital Working Capital Requirement
In a bankable cancer hospital working capital assessment, the requirement breaks into four components: inventory, receivables, operating cash buffer and supplier-credit adjustment.
Inventory
Oncology and chemotherapy drugs form the largest inventory component. Fast-moving chemotherapy molecules typically require 30-60 days of stock; less frequently used targeted-therapy agents may need 45-90 days given procurement lead times. Supportive care drugs (antiemetics, growth factors) and general pharmacy items generally require 30-45 days of cover.
Surgical consumables and implants present their own challenges. Research on surgical consumable stores in Indian hospitals found average internal lead times of approximately 17 days and external lead times of approximately 25 days, totalling about 44 days on average. Radiotherapy and imaging consumables (contrast media, dosimetry materials) are low-volume but high-cost items that must remain continuously available. Pathology and molecular diagnostic reagents and kits carry shelf-life constraints and must be procured in line with expected diagnostic volumes. General medical supplies and PPE turn over faster but still require 30-45 days of stock.
Operating a cancer facility requires substantial cash reserves for ongoing expenses, and inventory planning that accounts for expiry, cold-chain storage and variable procurement cycles is essential.
Receivables
Different payer categories create different collection timelines:
- Self-pay patients typically pay at discharge or provide partial advances; receivable days are near zero
- Private insurance and TPA patients under cashless arrangements are settled post-discharge, with credit periods of 30-45 days on average
- Ayushman Bharat and state health scheme reimbursements often take 60-120 days and can be irregular
- Corporate and institutional contracts may involve negotiated credit terms of 30-60 days
The payer mix significantly impacts the working capital requirements of cancer facilities. A hospital where 60% of revenue comes from insurance and government schemes will carry far higher receivables than one collecting 80% in cash, even at identical revenue levels.
Operating Cash Requirement
Beyond inventory and receivables, promoters must plan for at least 1-2 months of cash buffer covering net monthly operating expenses: salaries and professional fees; power, oxygen and utilities; housekeeping, security and laundry; biomedical waste management; clinical and IT software subscriptions; routine maintenance; insurance premiums; and marketing and referral-building expenditure during early years.
Creditors and Supplier Credit
Vendor credit on oncology drugs typically ranges from 15-45 days for established hospital clients, though novel or expensive molecules may require advance payment. Consumable and service-provider credit of 30 days is common. More profitable hospitals pay suppliers faster to avoid high interest rates or penalties, but assuming unrealistically long credit periods in a DPR will draw scrutiny from lenders. While good supplier credit reduces net funding needs, banks do not accept aggressive assumptions without evidence of vendor agreements.
In a properly linked financial model, these components should reconcile with projected balance sheet line items: inventories, trade receivables, cash and bank balances, and trade payables.
How to Calculate Cancer Hospital Working Capital Requirement
In practice, working capital for a cancer hospital is estimated using the operating-cycle approach, anchored to monthly revenue and expense projections from the DPR or the Cancer Hospital Revenue Model.
The formula: Operating Cycle = Inventory Holding Period (days) + Receivable Collection Period (days) minus Creditor Payment Period (days). A longer operating cycle means higher working capital per rupee of turnover.
Financial models for cancer hospitals should focus on inventory, receivables and cash buffers. Here is an illustrative calculation for a mid-sized 100-bed cancer hospital (all figures are illustrative only; actual requirements depend on project size, specialty mix, payer profile and operating assumptions):
| Particulars | Basis | Illustrative Amount (₹ Crore) |
|---|---|---|
| Pharmacy & Drug Inventory | 45 days of ₹2.40 Cr monthly drug/consumable purchases | 3.60 |
| Other Medical Consumables | 30 days of ₹0.60 Cr monthly consumable spend | 0.60 |
| Receivables | 60 days of ₹3.60 Cr monthly credit revenue | 7.20 |
| Operating Cash Requirement | 1 month of ₹2.40 Cr net operating expenses (ex-drugs) | 2.40 |
| Other Current Assets | Prepayments, advances | 0.20 |
| Less: Supplier Credit | 30 days of ₹2.40 Cr monthly purchases | (2.40) |
| Net Working Capital Requirement | 11.60 |
How the math works: if monthly drug and consumable purchases total ₹2.40 crore and the hospital holds 45 days of stock, inventory value is ₹2.40 crore multiplied by 45/30, equalling ₹3.60 crore. Credit revenue of ₹3.60 crore per month with 60-day collection means receivables outstanding at any time equal ₹3.60 crore multiplied by 60/30, or ₹7.20 crore. Supplier credit of 30 days on ₹2.40 crore of monthly purchases offsets ₹2.40 crore. The net requirement is the sum of all current assets minus creditors.
This cancer hospital working capital calculation should align with the same revenue, cost and payer-mix assumptions used in Cancer Hospital Financial Projections for DPR.
Working Capital Requirement During the Initial Ramp-Up Period
The first 12-24 months after commissioning are characterised by low occupancy, gradual build-up of OPD and day-care chemotherapy volumes, and incremental growth in radiotherapy fractions. This period typically produces the highest working capital stress in the hospital’s life.
During ramp-up, consultant retainers, senior oncology salaries, technical staff wages, power charges for high-end radiotherapy equipment, and quality-compliance costs remain almost fully fixed regardless of patient numbers. Capital expenditure in oncology includes high upfront costs for technology and equipment, but the recurring operating cost base is equally demanding from day one. Initial investment for a cancer facility can exceed $100 million, yet the working capital strain in the first year can be equally decisive for survival.
There is an important distinction between standard accounting working capital (current assets minus current liabilities at a point in time) and the “initial operating cash deficit” required to absorb early-stage losses until the hospital reaches break-even. In a DPR, I prefer to show separate estimates for: (a) steady-state working capital requirement at target capacity utilisation, and (b) additional liquidity buffer required for the first 12-18 months.
Underestimating ramp-up cash losses leads to delayed salaries, stock-outs of critical chemotherapy drugs, inability to pay equipment AMCs, and operational compromises that damage clinical quality and patient trust. Lenders may not fund 100% of ramp-up losses through working capital limits, so promoters should plan additional margin money or standby funding lines for this phase.
How Banks Assess Working Capital for a Cancer Hospital
Banks in India assess working capital for cancer hospital projects based on projected turnover, operating cycle analysis, security available and overall risk profile. There is no fixed percentage rule that applies uniformly.
Key assessment factors include:
- Projected revenue from each oncology stream: OPD, IPD, chemotherapy day care, radiotherapy, onco-surgery, diagnostics and pharmacy
- Expected inventory days for oncology medicines and consumables
- Receivable days for insurance/TPA and government scheme collections
- Creditor days based on vendor agreements
- Promoter’s net worth and contribution to working capital margin
In a cancer hospital working capital finance proposal, sanctioning banks examine the current ratio, working capital gap, and drawing power computed from stock and receivables. Prathima Cancer Hospital’s CRISIL rating, for example, flagged gross current assets of 127-143 days and receivables of approximately 97 days as a key risk factor, illustrating what lenders watch for.
Common working capital facilities used by oncology hospitals include Cash Credit (CC) against hypothecation of stocks and receivables, Overdraft (OD) against fixed deposits or other security, and Working Capital Demand Loan (WCDL) for specific short-term requirements. Exact products and terms vary by lender.
Banks also evaluate whether projected cash flows after working capital interest support satisfactory DSCR, and whether promoter contribution to working capital margin is adequate alongside term-loan obligations. Post-commissioning, banks monitor actual operations through stock statements, monthly financials and utilisation data, adjusting limits based on real performance.
A comprehensive DPR with integrated working capital analysis, structured through Cancer Hospital Project Cost & Means of Finance methodology, typically supports smoother bank appraisal.
Connection Between Working Capital, Financial Projections and DSCR
Working capital assumptions directly influence the projected balance sheet, cash flow statement, interest cost and DSCR. Increases in inventory and receivables over the initial years appear as “increase in working capital” outflows in cash flow from operations, absorbing cash even when P&L profits look comfortable. Hospitals with faster patient revenue collection report higher profit margins, and higher profitability correlates with a longer cash conversion cycle that can be sustained.
If the cancer hospital working capital requirement is understated, financial projections will overstate free cash available for term-loan instalments, producing an artificially high DSCR.
A simple illustration: assume annual credit revenue of ₹43.20 crore (₹3.60 crore per month). At 45-day receivable collection, outstanding receivables equal ₹5.40 crore. At 90 days, the same revenue produces ₹10.80 crore in outstanding receivables. The P&L shows identical income; but the balance sheet shows ₹5.40 crore of additional cash locked in receivables. That ₹5.40 crore is unavailable for interest payments or principal repayment, and DSCR drops even though accounting profit has not changed.
Lenders routinely stress-test projections by extending receivable assumptions or increasing inventory days to observe how DSCR behaves under conservative scenarios. The framework for capturing these movements is detailed in the Cancer Hospital Financial Projections for DPR methodology.
Practical Example: Illustrative Oncology Hospital Working Capital Calculation
This is a simplified, illustrative case for a proposed 100-bed cancer hospital in a Tier-2 Indian city. It demonstrates the logic of working capital assessment and is not a universal benchmark. Efficient working capital management reduces current asset holdings, but the starting point must reflect realistic operating assumptions.
Sample assumptions (one steady-state month):
- Monthly operating revenue: ₹6.00 crore
- Credit revenue (insurance, TPAs, schemes, corporate): 60%, or ₹3.60 crore
- Self-pay / cash: 40%, or ₹2.40 crore
- Drug and consumable purchases: 40% of revenue = ₹2.40 crore per month
- Operating expenses excluding drugs (salaries, power, maintenance, services): ₹2.40 crore per month
- Inventory holding: drugs 45 days, consumables 30 days
- Supplier credit: 30 days
- Operating cash buffer: 1 month of net non-drug operating expenses
Three scenarios based on receivable collection period:
Scenario A (30-day receivables): Receivables = ₹3.60 Cr x (30/30) = ₹3.60 Cr Net Working Capital = 3.60 + 0.60 + 3.60 + 2.40 + 0.20 minus 2.40 = ₹8.00 Crore
Scenario B (60-day receivables): Receivables = ₹3.60 Cr x (60/30) = ₹7.20 Cr Net Working Capital = 3.60 + 0.60 + 7.20 + 2.40 + 0.20 minus 2.40 = ₹11.60 Crore
Scenario C (90-day receivables): Receivables = ₹3.60 Cr x (90/30) = ₹10.80 Cr Net Working Capital = 3.60 + 0.60 + 10.80 + 2.40 + 0.20 minus 2.40 = ₹15.20 Crore
Without any change in revenue, extending receivable days from 30 to 90 requires approximately ₹7.20 crore of additional oncology hospital working capital funding. This is why payer mix and collection efficiency are among the most consequential variables in cancer hospital cash flow planning.
Common Mistakes in Cancer Hospital Working Capital Assessment
In hospital DPRs and CMA Data submissions, several recurring errors distort cancer hospital working capital assessment and create cash-flow problems after commissioning.
- Assuming 100% cash collection at discharge: ignoring TPA, insurance and government scheme payment delays understates receivables and overstates available cash. The consequence is an inability to meet salary and vendor obligations within weeks of opening.
- Underestimating chemotherapy inventory: applying general-hospital consumable norms to oncology understates inventory by a wide margin. Stock-outs of critical chemotherapy drugs disrupt treatment protocols and erode patient trust.
- Ignoring or double-counting supplier credit: some DPRs assume all purchases are paid immediately (inflating requirement); others assume 90-day vendor credit without supporting agreements (deflating it). Both distort the picture for lenders.
- Treating depreciation as a cash expense: depreciation is a non-cash charge and should not appear in working capital calculations, yet it is occasionally included.
- Unrealistic occupancy and ramp-up assumptions: projecting 70% occupancy in year one reduces apparent working capital needs but misrepresents reality. Working capital management is essential for hospital financial health, and realistic ramp-up modelling is part of that discipline.
- Ignoring seasonal or monthly variation: cancer treatment volumes and insurance payouts can vary month to month; a flat monthly assumption may miss peak cash-need periods.
- Preparing working capital estimates in isolation: when the working capital model is not reconciled with the projected balance sheet and cash flow, the overall DPR loses credibility with lenders.
Working Capital Planning in a Bankable Cancer Hospital DPR
A cancer hospital DPR must integrate project cost, means of finance, revenue model, operating expenses, working capital and debt repayment into one consistent financial story. Working capital is not a standalone appendix.
Total project cost should comprise: land and civil works; radiation bunker and specialised construction; medical equipment and diagnostics (see Cancer Hospital Equipment List & Cost); pre-operative and launch expenses; and a defined provision for working capital margin and initial ramp-up funding.
Working capital should be derived from the same assumptions used in the revenue model: projected OPD, IPD, chemotherapy sessions, radiotherapy fractions, surgeries, diagnostic volumes and payer mix. Year-wise working capital requirement, promoter’s margin contribution and proposed working capital loan for cancer hospital should flow through into the projected balance sheet and cash flow.
At ProjectReportBank.com, under my guidance, oncology centre working capital assessment is structured so that banks can clearly see: base requirement, promoter margin, requested banking limits and the impact on DSCR and repayment capacity. A well-prepared oncology centre project finance proposal treats working capital as an integral part of the plan, not as a residual plug figure.
FAQs on Cancer Hospital Working Capital Requirement
These questions address practical doubts often raised by cancer hospital promoters and clinicians during DPR and bank-finance discussions.
How much working capital is typically required for a cancer hospital in India?
There is no universal percentage that applies to every oncology hospital. Requirement depends on bed capacity, planned radiotherapy and chemotherapy load, payer mix, inventory policy and collection cycles. For mid-sized 50-100 bed cancer hospitals, steady-state working capital often ranges between ₹6-16 crore depending on city, specialty mix and credit-revenue proportion. Exact numbers must be customised through a detailed DPR and financial model; applying arbitrary thumb rules is not advisable.
How is cancer hospital working capital calculated in practice?
The standard approach uses the operating cycle: estimating days of inventory holding, receivable collection and creditor payment, then converting those days into rupee values using projected monthly revenue and purchase costs. The calculation should be directly linked to the hospital’s projected volumes and revenue model rather than generic industry averages.
Can banks finance working capital for an oncology hospital?
Many banks and financial institutions in India provide working capital finance facilities such as Cash Credit and Overdraft to eligible cancer hospitals, based on appraisal of project viability, security, promoter profile and regulatory norms. Availability, quantum and terms of sanctioned working capital vary by lender and are never guaranteed. Promoters should plan adequate margin money alongside bank finance.
Are chemotherapy medicines and oncology drugs part of working capital?
Chemotherapy, targeted therapy and other oncology medicines held for treatment are inventory (a current asset) in working capital assessment, not fixed assets. Only long-term medical equipment, bunker construction and similar items form part of capital expenditure. Drugs and consumables are recurring items financed through working capital.
What happens if the cancer hospital working capital requirement is underestimated in the DPR?
Underestimation leads to chronic cash shortages, delayed salaries and vendor payments, difficulty maintaining adequate chemotherapy stock, and pressure on clinical quality and services. From a financing perspective, liquidity stress causes irregular term-loan repayments, weaker DSCR than projected, and a strained relationship with stakeholders and lenders. Realistic assessment at the DPR stage helps avoid these results.
Conclusion
Working capital for a cancer hospital is not a secondary figure to be inserted after financial projections are complete. It is a core component of oncology project planning, directly linked to revenue assumptions, inventory policy, receivable cycle, supplier credit, operating expenses and ramp-up behaviour. The essential elements of a sound assessment include realistic payer-mix analysis, evidence-based inventory holding periods, and conservative collection-cycle assumptions.
A robust cancer hospital working capital requirement and assessment should logically connect with overall project planning: Project Cost leads to Means of Finance, which supports Revenue, which determines Working Capital, which flows into Financial Projections, Cash Flow, DSCR and ultimately Repayment Capacity.
If you are a promoter, doctor, oncologist or investor planning a cancer hospital in India and need assistance with a customised DPR, CMA Data, working capital assessment or project-finance documentation, you can reach CA Manish Gugliya through ProjectReportBank.com. The purpose is to help you present structured, realistic proposals to banks and financing institutions, grounded in practical financial analysis rather than generic templates.
Explore All Cancer Hospital DPR Guides
Continue exploring our complete series on Cancer Hospital project planning, financial projections, repayment capacity and bank finance.